[Bacillus Calmette-Guerin maintenance treatment in non-invasive bladder tumors: 1 year follow-up results of multicenter URO-BCG-4 trial].

[1]  R. Sylvester,et al.  Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. , 2013, European urology.

[2]  C. Pfister,et al.  Recommandations du comité de cancérologie de l’Association française d’urologie (CC-AFU) pour la bonne pratique des instillations endovésicales de BCG et de mytomycine C dans le traitement des tumeurs de la vessie n’envahissant pas le muscle (TVNIM) , 2012 .

[3]  H. Quintens,et al.  Recommandations en Onco-Urologie 2010 : Tumeurs urothéliales , 2010 .

[4]  K. Nakagawa,et al.  Discontinuance of bacille Calmette-Guérin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence. , 2009, Urology.

[5]  Kamel Ai,et al.  Low dose BCG regimen in T1 transitional cell carcinoma of the bladder: long term results. , 2009 .

[6]  H. Herr.  Is maintenance Bacillus Calmette-Guérin really necessary? , 2008, European urology.

[7]  L. Lacombe,et al.  Maintenance bacillus Calmette‐Guérin in high‐risk nonmuscle‐invasive bladder cancer , 2008, Cancer.

[8]  A. Imai,et al.  Low-dose instillation therapy with bacille Calmette-Guérin Tokyo 172 strain after transurethral resection: historical cohort study. , 2008, Urology.

[9]  L. Martínez-Piñeiro,et al.  Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. , 2008, European urology.

[10]  E. Solsona,et al.  A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. , 2007, European urology.

[11]  F. Saint,et al.  The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. , 2006, The Journal of urology.

[12]  D. Lamm.  Improving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression in Superficial Bladder Cancer , 2006 .

[13]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[14]  L. Martínez-Piñeiro,et al.  Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. , 2005, The Journal of urology.

[15]  R. Sylvester,et al.  Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. , 2003, European urology.

[16]  D. Lamm,et al.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.

[17]  J. L. Sebastian,et al.  Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer , 2002, BJU international.

[18]  J. Patard,et al.  Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer. , 2001, Urology.

[19]  D. Lamm,et al.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.

[20]  K. Tozawa,et al.  Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer. , 1996, The Journal of urology.

[21]  J. Nickel,et al.  Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. , 1992, The Journal of urology.

[22]  P. Bassi,et al.  A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? , 1991, The Journal of urology.

[23]  L. Kavoussi,et al.  Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer. , 1988, The Journal of urology.

[24]  W. Catalona,et al.  Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. , 1987, The Journal of urology.

[25]  W. Catalona,et al.  Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer. , 1986, Clinical immunology and immunopathology.

[26]  L. Boccon‐Gibod,et al.  SYSTEMIC COMPLICATIONS OF INTRAVESICAL BCG THERAPY FOR BLADDER CANCER , 1985, The Lancet.

[27]  A. Morales.  Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer. , 1984, The Journal of urology.

[28]  A. Sankila,et al.  Long-term Efficacy of Maintenance Bacillus Calmette-Guérin versus Maintenance Mitomycin C Instillation Therapy in Frequently Recurrent TaT 1 Tumours without Carcinoma In Situ : A Subgroup Analysis of the Prospective , Randomised FinnBladder I Study with a 20-Year Follow-up , 2009 .

[29]  F. Debruyne,et al.  Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer , 2005, Cancer Immunology, Immunotherapy.

[30]  A. Böhle,et al.  Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. , 2003, The Journal of urology.

[31]  P. Bassi,et al.  Improving the efficacy of BCG immunotherapy by dose reduction. , 1995, European urology.

[32]  H. Akaza,et al.  Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. , 1995, Cancer.

[33]  M. Wanamaker.  How much is enough? , 1976, Tic.